



Final Appraisal Recommendation

Valganciclovir (Valcyte[®]) powder for oral solution

Submission by:
Roche Products Ltd

Advice No: 0711 – June 2011

Recommendation of AWMSG

Valganciclovir (Valcyte[®]) powder for oral solution is recommended as an option for restricted use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor.

Valganciclovir (Valcyte[®]) powder for oral solution is restricted for use in patients who cannot take tablets or with a CrCl<10 (ml/min).

AWMSG is of the opinion that valganciclovir (Valcyte[®]) powder for oral solution is not suitable for shared care within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: